The problem with HIV There is a clear need for a HIV vaccine. However, a number of features of HIV make the development of a vaccine very challenging.
The genome of HIV-1 is susceptible to genetic recombination and has an error-prone reverse transcriptase enzyme. This leads to the continuous emergence of mutant HIV-1 variants, even within an individual, facilitating escape from the immune system and greatly complicating the development of a vaccine. Classical vaccine approaches, such as wholeinactivated HIV or protein subunit vaccines, which are aimed primarily at inducing neutralizing antibodies (NAbs), failed efficacy standards in human and macaque trials [1, 2] . This is likely a consequence of the vast diversity of HIV-1 strains, extensive glycosylation of the envelope protein, immunodominant variable loops that divert the immune response and effective masking of conserved regions. More recently, vaccine approaches that aimed for an induction and preservation of CD8 + T-cell responses by plasmid DNA or live-recombinant vectors expressing relevant antigen(s) have demonstrated that even a head-start for cellular immunity is no guarantee for the preservation of immune responses or a lower viralload set-point in HIV infection. Indeed, the recent STEP trial demonstrated that although vaccination with recombinant adenoviruses expressing HIV proteins elicited HIV-specific CD8 + T lymphocytes [3] , it did not protect against infection or reduce viral-load set-point in those individuals who became infected during follow-up [4] . These disappointing results demand the investigation of newer concepts in immunity to HIV. It is worth noting that the recently announced Thai HIV vaccine-efficacy trial using a Canarypox/protein prime/boost demonstrated a modest (31%) reduction in new infections. Some observers have suggested that this effect could be due to non-neutralizing or binding HIV antibodies [101] . Several newer HIV vaccine strategies are emerging, although most of the concepts are variations on T-cell or antibody-based ideas (Table 1) . There have been numerous calls for the development of more innovative HIV vaccines.
The generation of broadly reactive NAbs is an urgent priority for HIV vaccine development. NAbs can utilize mechanisms such as complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) in vivo [5] . Where NAbs act to inhibit the attachment of the virus and fusion between the cell and the virus, ADCC and CDC effector mechanisms can kill free virions
The failure of HIV vaccine concepts based upon either simple antibody or T-cell immunity means that newer concepts in immunity to HIV require urgent investigation. Antibody-dependent cellular cytotoxicity (ADCC) responses, utilizing the arms of humoral and innate immunity, have been studied for many years, but their role in controlling or preventing HIV-1 remains controversial. Newer technologies can now be applied to study and map ADCC responses. This permits experiments to purify and isolate HIV-specific ADCC antibodies and directly assess their role in preventing simian-HIV infections in macaques. Analogous to complexities in the quality and specificity of T-cell and neutralizing antibody immunity to HIV, it is likely that some ADCC antibodies will be more efficient than others in controlling HIV infection and limiting viral escape. Rationally defining broadly reactive ADCC antibodies with potent in vivo activity should allow the selection of the most appropriate ADCC-inducing vaccine antigens. This pathway towards manipulating ADCC antibodies, which control HIV infection, will ultimately improve our understanding of ADCC against HIV infection and potentially yield new HIV vaccine candidates. Despite the expanding knowledge of the potential of ADCC antibodies, little is known regarding the specific HIV-1 epitopes that stimulate ADCC. To date, only Env- [12] and Nef-specific [13] ADCC epitopes have been well characterized in HIV-1-infected subjects, initially mapped by ELISA using overlapping peptides. Progress in elucidating further ADCC epitopes has been slow, in part owing to the inefficient and complex nature of the historical assays for assessing ADCC responses (Table 2 ). Typical killing-based ADCC assays measured responses to large proteins; however, this assay is not suited to assessing specific responses to smaller peptides in order to map ADCC responses [14, 15] . A novel intracellular cytokine staining ADCC method has recently been developed that allows the fine mapping Modified to reduce expression of irrelevant Ag targets CD8-independent effector memory T cells [38] [39]
Multiple epitope vaccines: Universal T-cell vaccine Polytope 'coldspot' vaccine DNA Polytope of 270 CD8 epitopes Targets recombination 'coldspots' within HIV [40] [41]
New administration route: Nasal/vaginal/aerosol delivery Increased mucosal response [42] [43] [44] New augmentation: Electroporative delivery Cytokine coexpression (e.g., IL-15) Nanoparticles
Enhanced delivery of DNA to cells Boosting T-cell immunity Protects Ag delivery to dendritic cells [45] [46]
[47]
Novel host target: LINE-specific T cells Targets HIV-induced cellular proteins rather than HIV itself [48] Neutralizing antibodybased
Reverse immunization Immune complexes Self-replicating alphavirus/HIV chimera Antilipid Abs DNA construct to express mAb Abs complexed to gp120 with adjuvant Replication stops when immunity neutralizes vaccine Target cardiolipin on host monocytes to block infection [49] [50]
[51]
[52]
NK cell-based NK killing mediated by ADCC Utilizes NK cells from innate immunity Adapted from [53] .
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Designing immunity to HIV: manipulating antibody-dependent cellular cytotoxicity antibodies | Review of linear ADCC epitopes [16] . Compared with existing killing-based ADCC assays, no artificial cell line is required, and either the patient's or a healthy donor's NK cells, as the effector cells, can be tested for ADCC activity along with the assessment of NK cytokine production, chemokine production and the loss of perforin or granzymes [17] . The ability to map linear ADCC epitopes permits the identification of the particular ADCC antibody, which can then be studied for its potential to prevent HIV infection, or at least retard the disease.
Isolating pure ADCC antibodies
Monoclonal antibodies (mAbs) are proving increasingly useful adjuncts to therapy for a number of diseases, such as cancer and autoimmunity [18] , and they may also prove useful for treating HIV infection. A comparison of ADCC antibodies to NAbs within the sera of HIV-infected individuals has highlighted no significant correlation between the two types of antibodies [19] . However, ADCC antibodies expand earlier following seroconversion compared with NAbs [20] . This early development of ADCC antibodies leads to the anticipation that isolation of these antibodies and their development into a vaccine may be the 'needle in the haystack', which sews together the patches of many years of research. Since the development of methods to map specific HIV ADCC epitopes, purification of their antibodies from serum is promising to allow the assessment of their utility. Antibodies have been purified from patient sera with only antibodies of the IgG isotype having been shown to mediate ADCC [21] .
The more efficient IgG isotypes IgG1 and IgG3, but also to some extent IgG2 and other mAbs, in mouse sera have also been shown to mediate ADCC [22] .
Immunoaffinity chromatography
Antibodies are generally purified from serum or tissue culture supernatants using conventional methods of column chromatography (Table 3) . In respect to ADCC antibodies, the optimal technique for purification is most likely immuno affinity purification ( Figure 1A ). This method involves the covalent binding of pure antigen to a solid support, allowing the antibodies from the polyclonal sera to bind, first removing the unbound antibodies by a number of wash steps and then finally eluting the antibodies of interest. The strength of this method is to isolate the specific antibodies from a mixed polyclonal pool of sera. However, a disadvantage is that it requires large amounts of antigen and the elution conditions of the specific antibody may lead to some loss of the antibody activity. This technique of purification may also be further optimized by the use of activated beads, such as cyanogen bromide-activated agarose or coupling peptides to a protein carrier, which is then bound to the activated beads. This technique is efficient for high-affinity antibodies; however, if there is a low affinity between antigen-antibody binding this may hinder the amount of antibody binding to the antigen in the first place. An additional factor that influences the yield of purified antibody is the relative ease with which the antibody can be eluted; this will depend on the type and number of bonds that form at the antigen-antibody interaction site and can be manipulated by changing variables, such as pH. Purification of the specific ADCC antibodies by adapting these techniques will allow consideration of the biological utility of these antibodies and further their characterization.
Monoclonal ADCC antibody generation
An alternative approach to studying ADCC responses is to generate mAbs that recognize specific HIV epitopes. The usual techniques for generating mAbs have a disadvantage in that many of the mAbs generated will not retain robust ADCC activity, since the human Designing immunity to HIV: manipulating antibody-dependent cellular cytotoxicity antibodies | Review influenza human mAbs from subjects with prior infection [23] [24] [25] . This improved technique adapted to obtaining ADCC mAbs from HIV-infected subjects involves adding EBV, CpG oligonucleotides and irradiated filler peripheral blood mononuclear cells to CD22 + / IgA/D/M -B lymphocytes from HIV-positive subjects and screening growing cells for antibody production. Individual clonal B-cell lines are then obtained by limiting dilution (Figure 1B) . The resulting mAbs should retain ADCC activity since they are derived from the subject's own B cells.
More recently, there has been further develop ment in the generation of human mAbs by Wrammert et al., who describe a rapid cloning technique (within 30 days) to generate high-affinity human mAbs against the influenza virus [26] . The technique involves sorting human blood cells from antibody-secreting cells by flow cytometry and distributing these cells, one cell per well, into multiwell plates. PCR amplification of the heavy chain (V H ) and k isotype of light chain region (V k ) genes of each cell follows cDNA generation by reverse transcriptase. Finally subcloning and screening for mAb expression against the influenza subtypes completes the method. This technique was recently applied to studying large panels of monoclonal NAbs to HIV by first sorting memory B cells that have IgG on the surface binding fluorescent Env protein. This impressive study uncovered a large breadth of NAb in most subjects [27] . Lewis and colleagues recently found this method of cloning of Ig light and heavy genes to be technically more feasible than EBV transformation of B cells [28] . However, it is worth noting that when applied to ADCC, the Fc portion of the Ig molecules must also be cloned out to recombine into a fully competent ADCC mAb.
Many ADCC mAbs to Env may also have neutralizing activity and this can make it difficult to determine the utility of ADCC alone [29] . An elegant study by Hessell et al. demonstrated that removing the monoclonal NAbs capability to bind Fc receptors greatly reduced the ability of this NAb to mediate protection from a genetically engineered hybrid virus having an HIV envelope and an SIV core (SHIV) challenge in vivo, which correlated with reduced ADCC in vivo [6] . Dissecting the role of ADCC antibodies in control of HIV should be greatly facilitated by the recent development of rapid methods to generate fully human mAbs.
Evaluating 'useful' ADCC antibodies
A constructive debate has emerged in recent years regarding the specificity and functions of anti-HIV CD8 + T cells and how this information should be used to design better HIV vaccines. For example, CTLs that target conserved and functionally important regions of Gag are likely to incur larger 'fitness' costs to viral replication if escape mutations are accrued [30] . Furthermore, CTLs that express multiple cytokines and chemokines, and rapidly kill virus-infected cells are also likely to be more inducible by vaccination [31] . There is a growing appreciation that the quality of the antiviral immunity, rather than simply the quantity, will ultimately be more important in determining their efficiency in controlling and preventing HIV. What then are the potential parameters that should be analyzed in assessing the quality of anti-HIV ADCC responses (Table 4) ? A major issue for the efficacy of HIV-specific ADCC is that the majority of HIV-specific ADCC studied target the HIV-1 Env protein.
Env is highly variable between strains, although the largest differences are concentrated within variable loops. Env-specific ADCC may, unless extremely broad or targeted to some of the relatively conserved regions within Env, have limited utility against divergent HIV strains. Targeting ADCC to more conserved proteins, such as Gag, Pol and some of the regulatory/ accessory proteins may, if possible, be a more effective ADCC-based vaccine approach. Indeed, Gag-specific CD8 + CTLs are more effective than Env-specific CTLs in both humans and macaques [32, 33] -this may also be true for ADCC responses. One reason why Gag-specific CTL responses are relatively more effective is that immune escape often comes at the cost of significantly reduced viral replication. Indeed, it is likely, although not studied to date, that ADCC responses also force viral escape. HIVspecific ADCC epitopes that target functionally constrained viral sequences could, if they force viral escape, lead to less-fit viral strains and slow replication and disease progression.
Natural killer cells are major effector cells of ADCC antibodies. There is considerable heterogeneity among NK cell subsets and this impacts which subsets are activated by ADCC, and the number and type of effector functions triggered. Furthermore, there is considerable evidence of NK cell dysfunction during HIV infection, which may limit the effectiveness of ADCC responses. By comparison to CTLs [31] , it may be that polyfunctional NK cells (those able to express multiple effector molecules), and NK cells, which can rapidly degranulate to kill HIV-infected cells [17, 34] , may be the most effective cells to recruit by ADCC antibodies.
Although in vitro studies on the effectiveness of HIV-specific ADCC responses will help guide the rational selection of ADCCinducing vaccine antigens, there are opportunities to assess the potential in vivo effectiveness of ADCC responses targeting specific HIV epitopes in carefully planned studies of HIV-infected subjects. We suggest that one approach is for cohorts of antiretroviral therapynaive subjects to be mapped for epitope-specific ADCC responses [16, 17] . Rates of progressive disease (e.g., CD4
+ T-cell decline) can then be determined for each epitope. Similar approaches were performed studying the rates of disease for various HLA-restricted CTL epitopes, revealing highly useful CTL epitopes [35] .
Definitively assessing the in vivo protective capability of different ADCC antibodies can utilize SHIV challenge models in macaques. Individual or combinations of ADCC antibodies can be infused prior to virus exposure and virus levels assessed after exposure [6] . A number of HIV-1 genes have been inserted into SIV backbones (e.g., Env, Tat, Rev and parts of Pol [36, 37] ), although not all strains replicate to high levels or result in immunodeficiency. Theoretically, combinations of ADCC antibodies should offer broader coverage of divergent viral strains and/or limit opportunities for viral escape.
Conclusion
There is an urgent need to explore newer concepts in HIV vaccines. The development of simpler ADCC assays, the ability to map ADCC epitopes along with improved methods of purifying and generating mAbs now permits a more definitive evaluation of this utility of ADCC in protection against HIV infection.
Future perspective
There is a growing interest in harnessing ADCC antibodies and the innate immune system in the quest to develop effective HIV vaccines or immunotherapies. A path has been presented in this article on ways to better define, generate and evaluate the most effective ADCC antibodies. Although purified ADCC antibodies could be of direct utility as immunotherapy or immunoprophylaxis, the greatest public-health benefit from the study of HIV-specific ADCC could come from the ability to incorporate the most useful ADCC epitopes into novel preventative HIV vaccines. Protein targeted Conserved internal proteins are more antigenically similar across strains than Env protein [14, 32] Viral escape Escape at functionally constrained epitopes will inflict a bigger fitness cost on viral replication and slow disease [30] Antigen presentation Some epitopes may be better presented on the surface of HIV-infected cells and result in bigger reductions in viral replication [54] FcR binding Broader use of FcRs by the ADCC Fc portion may activate larger numbers of NK cells [58] Poly-functional NK cells ADCC-activated NK cells with the capability of expressing multiple cytokines/chemokines may be more efficient at reducing viral replication [31] Rapidity of killing by ADCC-activated NK cells
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Killing of virus-infected cells by ADCC-activated NK cells may most effectively suppress virus replication [17, 34, 55] ADCC epitopes associated with slow HIV progression Particular ADCC responses may be over-represented in subjects with a slow decline of CD4 T cells or low viral load [35] ADCC responses associated with prevention of SIV/HIV infection of macaques Designing immunity to HIV: manipulating antibody-dependent cellular cytotoxicity antibodies | Review Executive summary
